Nymox Pharmaceutical Corp (NYMX)
Nymox Pharmaceutical Corp (NYMX) was listed on Nasdaq from November 26, 1997 and stopped trading under the symbol NYMX on July 7, 2023.
- Listed On
- Nasdaq
- Listed Since
- November 26, 1997
- Stopped Trading
- July 7, 2023
- Employees
- 3
About Nymox Pharmaceutical Corp
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Frequently asked questions
What is NYMX?
Nymox Pharmaceutical Corp (NYMX) was listed on Nasdaq from November 26, 1997 and stopped trading under the symbol NYMX on July 7, 2023.
Every reported institutional holder, plus insider and congressional trades in NYMX, on SentiSense.